Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Viruses with RNA Genomes

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chronic Watery Diarrhea With Colonic Intraepithelial Lymphocytosis Refractory To Budesonide Treatment - A Case Report.

Zeitschrift fur Gastroenterologie·2026

Same author

Conversion of sleeve gastrectomy to different types of bipartitions: OATB, B-TB, and RYTB-a retrospective single-center study.

Updates in surgery·2025

Same author

Endoscopic Negative Pressure Therapy for Post-Sleeve Gastrectomy Proximal Staple-Line Leaks: A Single-Center Experience of 40 Patients.

Digestive surgery·2025

Same author

Short-term Results of Transit Bipartition to Promote Weight Loss After Laparoscopic Sleeve Gastrectomy.

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2023

Same author

A rare PRSS1 p.S127C mutation is associated with chronic pancreatitis and causes misfolding-induced ER-stress.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2022

Same author

Short- to medium-term results of single-anastomosis duodeno-ileal bypass compared with one-anastomosis gastric bypass for weight recidivism after laparoscopic sleeve gastrectomy.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2020

Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020

Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020

Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020

Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016

Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016

Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

[Viral hepatitis B und C].

Markus Reiser¹

¹Klinik für Innere Medizin, Klinikum Vest GmbH, Behandlungszentrum Paracelsus-Klinik Marl, Marl, Germany. m.reiser@paracelsus-klinik-marl.de

Medizinische Klinik (Munich, Germany : 1983)

|May 16, 2009

Summary

This summary is machine-generated.

Chronic hepatitis B (HBV) and C virus (HCV) infections are serious liver diseases. New antiviral therapies offer improved treatment strategies for controlling HBV and eliminating HCV, preventing severe complications.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Related Experiment Videos

Last Updated: Jun 23, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Area of Science:

Hepatology and Virology
Infectious Diseases Research

Context:

Chronic hepatitis B (HBV) and hepatitis C virus (HCV) infections pose significant global health challenges, leading to liver cirrhosis and hepatocellular carcinoma.
Current research focuses on developing novel antiviral agents and optimizing treatment protocols using molecular markers.

Purpose:

To review the current standard of care for chronic HBV and HCV infections.
To summarize recent advancements and emerging therapies in viral hepatitis treatment.

Summary:

Interferon alpha, while less common for HBV, remains crucial in pegylated or albumin-fused forms for HCV therapy.
Newer treatments include targeted therapies like nucleoside/nucleotide analogs and specific inhibitors for HCV protease and RNA polymerase.
The evolving landscape of antiviral substances necessitates updated treatment strategies.

Impact:

Improved management of viral hepatitis through optimized treatment regimens.
Potential for enhanced viral replication control in HBV and elimination in HCV.
Reduced incidence of hepatitis-associated complications, including liver cancer and mortality.